Catalyst Event
CSPC Pharmaceutical Group Ltd (1093) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
5/11/2026, 12:00:00 AM
Announced that its ADC drug SYS6010 was granted another Breakthrough Therapy Designation in China for treating esophageal squamous cell carcinoma. Estimated Low importance as breakthrough designations are positive but early-stage regulatory milestones.
Korean Translation
ADC 약물 SYS6010이 식도 편평 세포암 치료제로 중국에서 또다시 혁신치료제 지정을 받았다고 발표함. 혁신치료제 지정은 긍정적이나 초기 단계의 규제 마일스톤이므로 낮은 중요도로 예상됨.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
D&D Pharmatech Inc (347850) · Other
The 48-week top-line results from the Phase 2 clinical trial of 'DD01', a MASH treatment, are scheduled to be presented at the European Association for the Study of the Liver (EASL) Congress 2026 (May 27-30) as a Late-Breaking Abstract; high impact is estimated due to the significant market potential for MASH treatments, which is expected.
5/27/2026, 12:00:00 AM